摘要
目的:探究外周血癌胚抗原(CEA)、协同肿瘤红细胞花环率(ATER)及外周血循环肿瘤细胞(CTCs)对晚期肺腺癌患者化疗效果及预后的评估价值。方法:回顾性分析2015年1月-2018年5月抚州市第一人民医院肿瘤科收治的127例晚期肺腺癌患者的临床资料,患者均进行2个周期化疗。将患者根据化疗效果分为CR组(n=20)、PR组(n=46)、SD组(n=37)、PD组(n=24)。比较不同化疗效果患者外周血CEA、ATER及CTCs差异;使用Spearman法分析患者外周血CEA、ATER与晚期肺腺癌患者化疗效果的相关性。全部晚期肺腺癌患者均随访3年,根据患者是否死亡分为存活组(n=49)、死亡组(n=78),比较不同预后结局晚期肺腺癌患者外周血CEA、ATER及CTCs差异,使用受试者特征(ROC)曲线分析晚期肺腺癌患者外周血CEA、ATER及CTCs对死亡结局的预测效能。结果:不同化疗效果患者外周血CEA、ATER及CTCs比较,差异均有统计学意义(P<0.05)。Spearman分析结果显示,晚期肺腺癌患者外周血CEA与患者化疗效果正相关(r_(s)=0.871,P<0.05),外周血ATER与患者化疗效果负相关(r_(s)=-0.889,P<0.05)。存活组患者外周血CEA水平、CTCs阳性率均低于死亡组,外周血ATER水平高于死亡组(P<0.05)。ROC曲线结果显示,外周血CEA、ATER及CTCs预测晚期肺腺癌患者死亡结局的AUC分别为0.814、0.937、0.641(P<0.05)。结论:外周血CEA、ATER及CTCs均可用于晚期肺腺癌患者的化疗效果评估及预后预测。
Objective:To explore the evaluated value of peripheral blood carcinoembryonic antigen(CEA),associated tumor erythrocyte rosette(ATER)and peripheral blood circulating tumor cells(CTCs)on chemotherapy effect and prognosis in patients with advanced lung adenocarcinoma.Method:The clinical data of 127 patients with advanced lung adenocarcinoma treated in Department of Oncology of the First People’s Hospital of Fuzhou were retrospectively analyzed from January 2015 to May 2018,all patients received 2 cycles of chemotherapy.The patients were divided into CR group(n=20),PR group(n=46),SD group(n=37)and PD group(n=24)according to chemotherapy effect.The peripheral blood CEA,ATER and CTCs of patients with different chemotherapy effects were compared;and Spearman method were used to analyze the correlation between peripheral blood CEA,ATER and chemotherapy effect in patients with advanced lung adenocarcinoma.All patients with advanced lung adenocarcinoma were followed up for 3 years,and they were classified into the survival group(n=49)and the death group(n=78)by means of whether the patients died or not.The differences in peripheral blood CEA,ATER and CTCs were compared among patients with advanced lung adenocarcinoma with different prognosis outcomes.Receiver operating characteristic(ROC)curve was applied to analyze the predictive efficiency of peripheral blood CEA,ATER and CTCs on death outcome in patients with advanced lung adenocarcinoma.Result:There were significant differences in peripheral blood CEA,ATER and CTCs among patients with different chemotherapy effects(P<0.05).Spearman analysis results showed that peripheral blood CEA in patients with advanced lung adenocarcinoma was positively correlated with chemotherapy effect(r_(s)=0.871,P<0.05),and peripheral blood ATER was negatively correlated with chemotherapy effect(r_(s)=-0.889,P<0.05).The peripheral blood CEA level and CTCs positive rate in the survival group were lower than those in the death group while the peripheral blood ATER level in the survival group
作者
李锄云
LI Chuyun(The First People’s Hospital of Fuzhou,Jiangxi Province,Fuzhou 344000,China)
出处
《中国医学创新》
CAS
2022年第34期44-48,共5页
Medical Innovation of China
基金
抚州市指导性科技计划项目(抚科计字[2018]5号-5)。
关键词
癌胚抗原
协同肿瘤红细胞花环率
外周血循环肿瘤细胞
晚期肺腺癌
化疗
Carcinoembryonic antigen
Associated tumor erythrocyte rosette
Peripheral blood circulating tumor cells
Advanced lung adenocarcinoma
Chemotherapy
